Luminex Co. (NASDAQ:LMNX) Stake Increased by DekaBank Deutsche Girozentrale

DekaBank Deutsche Girozentrale grew its holdings in shares of Luminex Co. (NASDAQ:LMNX) by 22.3% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,900 shares of the medical instruments supplier’s stock after acquiring an additional 4,000 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Luminex were worth $613,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. NumerixS Investment Technologies Inc bought a new stake in shares of Luminex during the fourth quarter valued at approximately $39,000. Amundi Pioneer Asset Management Inc. grew its position in Luminex by 32.4% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 4,500 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 1,100 shares in the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new position in Luminex during the 4th quarter worth approximately $100,000. Meeder Asset Management Inc. grew its position in Luminex by 11.1% during the 1st quarter. Meeder Asset Management Inc. now owns 4,925 shares of the medical instruments supplier’s stock worth $113,000 after purchasing an additional 491 shares in the last quarter. Finally, LS Investment Advisors LLC purchased a new position in Luminex during the 4th quarter worth approximately $127,000. Institutional investors own 84.71% of the company’s stock.

Luminex stock opened at $21.71 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.70 and a current ratio of 3.99. Luminex Co. has a 12 month low of $20.24 and a 12 month high of $35.37. The firm has a market cap of $969.71 million, a PE ratio of 126.82, a P/E/G ratio of 19.96 and a beta of 0.81.

Luminex (NASDAQ:LMNX) last posted its quarterly earnings results on Monday, May 6th. The medical instruments supplier reported ($0.07) EPS for the quarter, missing the consensus estimate of $0.07 by ($0.14). Luminex had a net margin of 2.55% and a return on equity of 1.62%. The company had revenue of $82.41 million for the quarter, compared to analysts’ expectations of $83.10 million. During the same quarter in the prior year, the firm earned $0.30 earnings per share. The company’s revenue was down .3% on a year-over-year basis. As a group, equities analysts expect that Luminex Co. will post 0.07 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Thursday, June 20th will be issued a dividend of $0.06 per share. This represents a $0.24 annualized dividend and a dividend yield of 1.11%. The ex-dividend date of this dividend is Wednesday, June 19th. Luminex’s dividend payout ratio is currently 50.00%.

Several research firms have weighed in on LMNX. BidaskClub cut shares of Luminex from a “hold” rating to a “sell” rating in a research report on Tuesday, April 16th. ValuEngine cut shares of Luminex from a “strong-buy” rating to a “buy” rating in a research report on Monday, March 11th. Zacks Investment Research upgraded shares of Luminex from a “sell” rating to a “hold” rating in a research report on Tuesday, March 19th. Finally, William Blair reiterated a “market perform” rating on shares of Luminex in a research report on Tuesday, May 7th. One investment analyst has rated the stock with a sell rating and five have given a hold rating to the company’s stock. Luminex presently has an average rating of “Hold” and a consensus price target of $31.33.

ILLEGAL ACTIVITY WARNING: “Luminex Co. (NASDAQ:LMNX) Stake Increased by DekaBank Deutsche Girozentrale” was originally published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this story on another domain, it was stolen and reposted in violation of US & international copyright and trademark law. The legal version of this story can be read at https://transcriptdaily.com/2019/06/13/luminex-co-nasdaqlmnx-stake-increased-by-dekabank-deutsche-girozentrale.html.

Luminex Profile

Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.

Featured Article: Dollar Cost Averaging

Want to see what other hedge funds are holding LMNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Luminex Co. (NASDAQ:LMNX).

Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.